Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Efficacy of fenugreek seed extract on men's psychological and physical health: a randomized placebo-controlled double-blind clinical trial.

  • 2020-05-22
  • Journal of complementary & integrative medicine 18(2)
    • Heather A Hausenblas
    • Kara L Conway
    • Kevin R M Coyle
    • Emily Barton
    • Lacie D Smith
    • Michael Esposito
    • Charles Harvey
    • Dennis Oakes
    • David R Hooper

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 57
Population
57 healthy male volunteers, mean age 26.1 years
Methods
Randomized double-blind placebo-controlled trial, parallel design, fenugreek 400 mg/d, fenugreek 500 mg/d, or placebo
Blinding
Double-blind
Duration
60 days
Funding
Unclear

Objectives

Limited research has examined the effects of fenugreek (Trigonella foenum-graecum L.) supplementation to improve healthy younger men's aging male symptoms. The study objective was to examine whether a fenugreek seed extract would improve healthy men's aging male symptoms, health-related quality of life (HRQoL), grip strength, and anxiety.

Methods

Randomized double-blind placebo-controlled trial was employed, using a parallel design, with assessments at baseline, Day 30, and Day 60. Healthy male volunteers (n = 57, mean age = 26.1 years) were randomized to: fenugreek 400 mg/d (n = 19), fenugreek 500 mg/d (n = 19), or placebo group (n = 19).

Results

The fenugreek groups reported significant improvements in aging male symptoms, anxiety levels, grip strength, and indicators of HRQoL compared to the placebo group, p's < 0.05. No adverse events were reported.

Conclusion

Fenugreek supplementation is an effective nutritional intervention for improving aging male symptoms, anxiety levels, grip strength, and aspects of HRQoL in healthy recreationally active men. Future researchers are encouraged to examine the health and ergogenic effects of fenugreek supplementation in hypogonadal and older populations.

Trial registration

Clinicaltrials.gov identifier NCT03528538.

Research Insights

Adverse Events Reported

  • Fenugreek SeedOverall tolerability

    No adverse events were reported.

    Finding
    Reported
Back to top